The Street’s Key Stock Analysts Research Reports

$AABA, $ASH, $AZO, $LLY, $KBR, $TLC

Daily HeffX-LTN reviews dozens of  the Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. Some reports cover stocks to buy, and others cover stocks to sell or avoid.

Below is a list of The Street’s Key analysts outlook for Key issues for Friday as follows:

Altaba Inc. (NASDAQ:AABA) was raised to Buy from Hold at Morningstar Research. The 52-wk trading range for the company, which has a large position in Alibaba Inc. (NASDAQ:BABA), has been 54.75 – 82.45. The Wall Street consensus price target is 80. The stock ended trading on Thursday at 57.97.

Ashland Global Holdings Inc. (NYSE:ASH) was raised to Overweight from Neutral at JPMorgan. The 52-wk trading range for the stock is 64.81 – 86.63, and the consensus price target is 94.80. The shares closed Thursday at 70.68, up nearly 4% on the day

AutoZone Inc. (NYSE:AZO) saw its price target raised to 870 from 800 at Morgan Stanley. The firm also raised its earnings estimates for the retail car parts giant for Y 2019. The new price target compares with the consensus target of 919.18. The stock ended trading on Thursday at 843.04.

Eli Lilly and Co. (NYSE:LLY): Analysts reiterated LLY with a Buy rating and a 135 price target at Argus. That compares with a consensus target of 117.88. The firm sees volume growth and expanded indications for existing drugs, along with potential regulatory approvals, as catalysts for growth in Y 2019. The stock closed Thursday at 112.89.

KBR Inc. (NYSE:KBR) was named the Top 2019 pick at MKM Partners, which has set a 25 price target. The consensus target is 23.25, and the stock closed trading on Thursday at 15.07.

Taiwan Liposome Co. Ltd. (NASDAQ:TLC): Analysts started TLC with an Overweight rating and an 11 price target at Cantor Fitz. The consensus target is 11. The analyst noted that the company’s expertise and experience with liposome science have yielded the BioSeizer and NanoX formulation technologies that, in its view, have the potential to improve the pharmacologic and therapeutic potential of approved pharmacophores to treat various medical disorders. The stock closed Thursday at 5.50.

Have a terrific weekend.

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH